948 resultados para 612.044
Resumo:
Magdeburg, Univ., Fak. für Naturwiss., Diss., 2014
Resumo:
Magdeburg, Univ., Med. Fak., Diss., 2015
Resumo:
Magdeburg, Univ., Med. Fak., Habil.-Schr., 2014
Resumo:
Magdeburg, Univ., Med. Fak., Diss., 2015
Resumo:
O bagaço de cana-de-açúcar "in natura" (BIN) associado ou não ao bicarbonato de sódio foi testado como substituto do feno de gramínea como fonte de fibra longa para rações de ruminantes balanceadas com altas proporções de bagaço auto-hidrolisado (BAH). A ração básica (I) continha 54% BAH; 10% milho grão; 25% farelo de algodão; 8% feno de gramínea; 0,9% calcáreo; 0,5% uréia; e 1,5% premix mineral, base seca. As rações II e III continham BIN e BIN mais bicarbonato de sódio (1,1%, base seca) respectivamente em substituição ao feno de gramínea da ração I. Foram usados bovinos Nelore machos não castrados e fêmeas (18 de cada sexo) em crescimento com médias iniciais de peso vivo e idade de 199 kg e 11 meses. O delineamento estatístico usado foi um fatorial com 3 rações e dois sexos, com dois animais por parcela. O período de adaptação foi de 15 dias e o experimental de 87 dias. Os dados para GPV (kg/dia); ingestão de MS (% PV); conversão alimentar (kg MS/Kg GPV); e pH fecal foram de: 0,909; 2,79; 7,41; e 6,46 para a ração I; 0,867; 2,65; 7,24; e 6,57 para a ração II; e 1,019; 2,88; 7,03 e 6,73 para a ração III. A ração III foi superior rações I e II para ganho de peso (P < 0,05), e apresentou um pH fecal maior do que o da ração I (P < 0,05). Os machos foram superiores às fêmeas em ganho de peso (1,044 vs 0,820; P < 0,01) e conversão alimentar (6,7vs7,7kg MS/Kg GPV; P < 0,01). Foi observada uma correlação negativa signi ficativa (P < 0,05) entre conversão alimentar e pH fecal (r =-0,50). Os elevados níveis de consumo (2,8% PV), o baixo pH do BAH (2,9 a 3,4), e a aparente baixa atividade de ruminação observados sugerem que o pH, a nível de rume e de trato digestivo inferior, é um fator limitante em dietas com altas proporções de BAH.
Resumo:
O cascudo Loricariichthys platymetopon foi capturado pela primeira vez recentemente na região média do rio Paranapanema, tornando-se uma espécie abundante desde então. Aspectos reprodutivos dessa espécie foram analisados neste estudo, com base numa amostra de 1.044 exemplares provenientes do reservatório de Capivara. Foram avaliados a abundância, proporção sexual, RGS, IAR e o diâmetro dos ovócitos. Locais distantes da barragem apresentaram as maiores abundâncias, as fêmeas atingiram maiores tamanhos que os machos e a proporção sexual variou entre os trechos de coleta. A reprodução ocorreu principalmente nos meses quentes, com intensidade moderada; as médias da fecundidade absoluta e da relativa foram de 663,95 ± 141,99 ovócitos e 4,9 ± 1,24 ovócitos/g, respectivamente. A desova ocorreu de modo parcelado e o diâmetro máximo médio do ovócito maduro foi de 3,67 mm. Os dados foram relacionados com o sucesso da espécie na ocupação da região.
Resumo:
In a market where firms with different characteristics decide upon both the level of emissions and their reports, we study the optimal audit policy for an enforcement agency whose objective is to minimize the level of emissions. We show that it is optimal to devote the resources primarily to the easiest-to-monitor firms and to those firms that value pollution the less. Moreover, unless the budget for monitoring is very large, there are always firms that do not comply with the environmental objective and others that do comply; but all of them evade the environmental taxes.
Resumo:
"Vegeu el resum a l'inici del document del fitxer adjunt."
Resumo:
Al llarg dels últims anys l’òxid nítric (NO) i el monòxid de carboni (CO) han estat investigats com dos neurotransmissors gasosos del tracte gastrointestinal. Algunes dades demostren que el sulfur d’hidrogen (H2S) podria ser el tercer neurotransmissor gasos a nivell central i perifèric. Objectiu: valorar si el H2S compleix els requisits per ser considerat com el tercer neurotransmissor gasos a nivell del sistema nerviós entèric. Mètodes: la motilitat espontània de preparacions de múscul llis circular de mostres de còlon sigma humà i còlon mig de rata es van determinar in vitro mitjançant la tècnica de banys d’òrgans. El hidrogensulfur de sodi (NaHS) va ser utilitzat com donador de H2S. Resultats: 1- El NaHS va inhibir de forma concentració depenent la motilitat espontània en presència de bloqueig neural amb Tetrodotoxina (TTX 1 μM) (IC50 101±18 μM rata n=10; 329±86 μM humà n=18). 2- Aquesta relaxació es va veure reduïda per ODQ 10 μM, un inhibidor de la guanilat ciclasa, en còlon mig de rata (n=5). En humà a més de ser reduïda per ODQ 10μM (n=6), també ho va ser per SQ 22,536 100 μM (n=10), un inhibidor de l’adenilat ciclasa, i per L-NNA 1 mM (n=8), un inhibidor de la sintesi de NO. 3- En còlon de rata la incubació amb D,L-Propargilglicina 2 mM (PAG), un inhibidor de la síntesi de H2S, va incrementar la motilitat tant en situació control (10,05±2,06 vs 17,46±3,37 g•min-1 AUC, P&0,001, n=10) com en presència de TTX 1μM (14,45±7,28 vs 21,67±10,05 g•min-1 AUC, P&0,01, n=7). Conclusió: el H2S compleix part dels criteris per ser considerat un neurotransmissor gasos inhibitori en el tracte gastrointestinal: la inhibició de la seva síntesi incrementa la motilitat intestinal i la seva addició exògena produeix relaxació de la musculatura llisa intestinal.
Resumo:
We analyse the role of time-variation in coefficients and other sources of uncertainty in exchange rate forecasting regressions. Our techniques incorporate the notion that the relevant set of predictors and their corresponding weights, change over time. We find that predictive models which allow for sudden rather than smooth, changes in coefficients significantly beat the random walk benchmark in out-of-sample forecasting exercise. Using innovative variance decomposition scheme, we identify uncertainty in coefficients' estimation and uncertainty about the precise degree of coefficients' variability, as the main factors hindering models' forecasting performance. The uncertainty regarding the choice of the predictor is small.
Resumo:
Background: There is currently no identified marker predicting benefit from Bev in patients with breast cancer (pts). We monitored prospectively 6 angiogenesis-related factors in the blood of advanced stage pts treated with a combination of Bev and PLD in a phase II trial of the Swiss Group for Clinical Cancer Research, SAKK.Methods: Pts received PLD (20 mg/m2) and Bev (10 mg/kg) every 2 weeks for a maximum of 12 administrations, followed by Bev monotherapy until progression or severe toxicity. Blood samples were collected at baseline, during treatment and at treatment discontinuation. Enzyme-linked immunosorbent assays (Quantikine, R&DSystems and Reliatech) were used to measure vascular endothelial growth factor (VEGF), placental growth factor (PlGF), matrix metalloproteinase 9 (MMP-9) and soluble VEGF receptors -1, -2 and -3. The natural log-transformed (ln) data for each factor was analyzed by analysis of variance (ANOVA) model to investigate differences between the mean values of the subgroups of interest (where a = 0.05), based on the best tumor response by RECIST.Results: 132 samples were collected in 41 pts. The mean of baseline ln MMP-9 levels was significantly lower in pts with tumor progression than those with tumor response (p=0.0202, log fold change=0.8786) or disease control (p=0.0035, log fold change=0.8427). Higher MMP-9 level was a significant predictor of superior progression free survival (PFS): p=0.0417, hazard ratio=0.574, 95% CI=0.336-0.979. In a multivariate cox proportional hazards model, containing performance status, disease free interval, number of tumor sites, visceral involvement and prior adjuvant chemotherapy, using stepwise regression baseline MMP-9 was still a statistically 117P Table 1. SOLTI-0701* AC01B07* NU07B1* SOR+CAP N=20 PL+CAP N=33 SOR+ GEM/CAP N=23 PL+ GEM/CAP N=27 SOR+PAC N=48 PL+PAC N=46 Baseline characteristics Age, median (range), y 49 (32-72) 53 (30-78 54 (32-69) 57 (31-82) 50 (27-80) 52 (23-74) AJCC stage, n (%) IIIB/IIIC 3 (15) 6 (18) 0 (0) 3 (11) 8 (17) 9 (20) IV 17 (85) 27 (82) 23 (100) 24 (89) 40 (83) 37 (80) Metastatic site, n (%) Non-visceral 3 (15) 6 (18) 7 (30) 6 (22) 9 (19) 17 (37) Visceral 17 (85) 27 (82) 16 (70) 21 (78) 39 (81) 29 (63) Prior metastatic chemo, n (%) 8 (40) 15 (45) 21 (91) 25 (93) - - Efficacy PFS, median, mo 4.3 2.5 3.1 2.6 5.6 5.5 HR (95% CI)_ 0.60 (0.31, 1.14) 0.57 (0.30, 1.09) 0.86 (0.50, 1.45) 1-sided P value_ 0.055 0.044 0.281 Overall survival, median, mo 17.5 16.1 Pending 14.7 18.2 HR (95% CI)_ 0.98 (0.50, 1.89) 1.11 (0.64, 1.94) 1-sided P value_ 0.476 0.352 Safety N=20 N=33 N=22 N=27 N=46 N=46 Tx-emergent Grade 3/4, n (%) 15 (75) 16 (48) 20 (91) 17 (63) 36 (78) 16 (35) Grade 3§ hand-foot skin reaction/ syndrome 8 (40) 5 (15) 8 (36) 0 (0) 14 (30) 2 (4) *Efficacy results based on intent-to-treat population and safety results based on safety population (pts who received study drug[s]); _Cox regression within each subgroup; _log-rank test within each subgroup; §maximum toxicity grade for hand-foot skin reaction/syndrome; AJCC, American Joint Committee on Cancer mittedabstractsª The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com Downloaded from annonc.oxfordjournals.org at Bibliotheque Cantonale et Universitaire on June 6, 2011 significant factor (p=0.0266). The results of the other measured factors were presented elsewhere.Conclusions: Higher levels of MMP-9 could predict tumor response and superior PFSin pts treated with a combination of Bev and PLD. These exploratory results justify further investigations of MMP-9 in pts treated with Bev combinations in order to assess its role as a prognostic and predictive factor.Disclosure: K. Zaman: Participation in advisory board of Roche; partial sponsoring ofthe study by Roche (the main sponsor was the Swiss Federation against Cancer (Oncosuisse)). B. Thu¨rlimann: stock of Roche; Research grants from Roche. R. vonMoos: Participant of Advisory Board and Speaker honoraria
Resumo:
Objectives: The AMS 800TM is the current artificial urinary sphincter (AUS) for incontinence due to intrinsic sphincter deficiency. Despite good clinical results, technical failures inherent to the hydraulic mechanism or urethral ischemic injury contribute to revisions up to 60%. We are developing an electronic AUS, called ARTUS to overcome the rigors of AMS. The objective of this study was to evaluate the technical efficacy and tissue tolerance of the ARTUS system in an animal model.Methods: The ARTUS is composed by three parts: the contractile unit, a series of rings and an integrated microprocessor. The contractile unit is made of Nitinol fibers. The rings are placed around the urethra to control the flow of urine by squeezing the urethra. They work in a sequential alternative mode and are controlled by a microprocessor. In the first phase a three-rings device was used while in the second phase a two-rings ARTUS was used. The device was implanted in 14 sheep divided in two groups of six and eight animals for study purpose. The first group aimed at bladder leak point pressure (BLPP) measurement and validation of the animal model; the second group aimed at verifying mid-term tissue tolerance by explants at twelve weeks. General animal tolerance was also evaluated.Results: The ARTUS system implantation was uneventful. When the system was activated, the BLPP was measured at 1.038±0.044 bar (mean±SD). Urethral tissue analysis did not show significant morphological changes. No infection and no sign of discomfort were noted in animals at 12 weeks.Conclusions: The ARTUS proved to be effective in continence achievement in this study. Histological results support our idea that a sequential alternative mode can avoid urethral atrophy and ischemia. Further technical developments are needed to verify long-term outcome and permit human use.
Resumo:
Circulating levels of adiponectin, a hormone produced predominantly by adipocytes, are highly heritable and are inversely associated with type 2 diabetes mellitus (T2D) and other metabolic traits. We conducted a meta-analysis of genome-wide association studies in 39,883 individuals of European ancestry to identify genes associated with metabolic disease. We identified 8 novel loci associated with adiponectin levels and confirmed 2 previously reported loci (P = 4.5×10(-8)-1.2×10(-43)). Using a novel method to combine data across ethnicities (N = 4,232 African Americans, N = 1,776 Asians, and N = 29,347 Europeans), we identified two additional novel loci. Expression analyses of 436 human adipocyte samples revealed that mRNA levels of 18 genes at candidate regions were associated with adiponectin concentrations after accounting for multiple testing (p<3×10(-4)). We next developed a multi-SNP genotypic risk score to test the association of adiponectin decreasing risk alleles on metabolic traits and diseases using consortia-level meta-analytic data. This risk score was associated with increased risk of T2D (p = 4.3×10(-3), n = 22,044), increased triglycerides (p = 2.6×10(-14), n = 93,440), increased waist-to-hip ratio (p = 1.8×10(-5), n = 77,167), increased glucose two hours post oral glucose tolerance testing (p = 4.4×10(-3), n = 15,234), increased fasting insulin (p = 0.015, n = 48,238), but with lower in HDL-cholesterol concentrations (p = 4.5×10(-13), n = 96,748) and decreased BMI (p = 1.4×10(-4), n = 121,335). These findings identify novel genetic determinants of adiponectin levels, which, taken together, influence risk of T2D and markers of insulin resistance.
Resumo:
La malaltia renal crònica (MRC) inicial s’ha definit com un marcador de risc cardiovascular susceptible d’intervenció terapèutica preventiva. Aquesta relació ha estat poc estudiada al nostre entorn. Objectius: Determinar si la MRC s’associa a un increment de risc de morbiditat i mortalitat al nostre entorn. Disseny: Estudi observacional prospectiu d’una cohort poblacional de Girona de 31.612 individus de 35-74 anys. Resultats: La MRC estadi 3 sense albuminúria no incrementa el risc de malaltia cardiovascular en població general de baix risc cardiovascular. L’albuminúria&20mg/L i els estadis 4-5 de MRC s’associen a un increment de risc de morbiditat cardiovascular i mortalitat global.
Resumo:
BACKGROUND: During stress, vasopressin is a potent synergistic factor of CRH as a hypothalamic stimulator of the HPA axis. The measurements of CRH and vasopressin levels are cumbersome because of their instability and short half-life. Copeptin is a more stable peptide stoichiometrically released from the same precursor molecule. The aim of our study was to compare copeptin and cortisol levels in different stress situations. METHODS: Three groups of patients with increasing stress levels were investigated: a) healthy controls without apparent stress (n=20), b) hospitalized medical patients with moderate stress (n=25) and c) surgical patients 30 minutes after extubation, with maximal stress (n=29). In all patients we assessed cortisol and copeptin levels. Copeptin levels were measured with a new sandwich immunoassay. RESULTS: Cortisol levels in controls were (median, IQ range, 486 [397-588] nmol/L), not significantly different as compared to medical patients (438 [371-612] nmol/L, p=0.69). Cortisol levels in surgical patients after extubation were higher (744 [645-1062] nmol/L p<0.01 vs controls and medical patients). Copeptin levels in controls were 4.3 [3.2-5.5] pmol/L, which was lower as compared to medical patients (17.5 [6.4-24.1], p<0.001) and surgical patients after extubation (67.5 [37.8-110.0] pmol/L, p<0.001). The correlation between copeptin levels and cortisol was r=0.46, p<0.001. CONCLUSION: Copeptin is a novel marker of the individual stress level. It more subtly mirrors moderate stress as compared to cortisol values.